首页> 中文期刊> 《中国医院用药评价与分析》 >扎莱普隆治疗失眠症的疗效观察

扎莱普隆治疗失眠症的疗效观察

         

摘要

目的:分析扎莱普隆对失眠症的临床疗效及安全性。方法:选择齐齐哈尔市精神卫生中心2013年3月—2014年10月收治的98例失眠症患者作为研究对象。按随机数字表法将患者分为观察组50例和对照组48例;观察组患者应用扎莱普隆,对照组患者应用佐匹克隆,比较2组患者的焦虑自评量表( self-rating anxiety scale ,SAS)、匹兹堡睡眠质量指数( pittsburgh sleep quality index,PSQI)得分变化情况,临床疗效以及不良反应发生情况。结果:治疗后,观察组患者SAS及 PSQI 得分分别为(38.35±4.58)、(13.18±5.72)分,显著低于对照组的(41.58±4.62)、(18.52±4.08)分,差异有统计学意义(P<0.05);观察组患者不良反应发生率为8.00%(4/50),明显低于对照组患者37.50%(18/48),差异有统计学意义(P<0.05);观察组患者总有效率为80.00%(40/50),高于对照组的75.00%(36/48),差异无统计学意义(P>0.05)。结论:采用扎莱普隆治疗失眠症不仅安全性好,临床疗效显著,可有效缓解患者焦虑及抑郁情绪。%OBJECTIVE:To analyze the clinical efficacy and safety of zaleplon in treatment of insomnia . METHODS:98 cases of insomnia admitted into Qiqihaer Mental Health Center from Mar .2013 to Oct.2014 were selected to be divided into observation group (50 cases) and control group (48 cases) via the random number table .The observation group were treated with zaleplon ,while the control group received zopiclone ,the self-evaluation of anxiety scale( SAS) ,Pittsburgh sleep quality index ( PSQI) score and clinical efficacy and incidence of adverse drug reactions were compared between two group of patients .RESULTS:After treatment ,the SAS and SDS score of observation group were respectively (38.35 ±4.58) and (13.18 ±5.72),significantly lower than that of control group (41.58 ±4.62) and (18.52 ±4.08),with statistically significant difference (P0.05 ) . CONCLUSIONS:The clinical efficacy of zaleplon in treatment of insomnia is not only safe but significant , and can effectively relieve the patients'anxiety and depression .

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号